uploads/2018/07/dna-1811955_1280-1.jpg

Gauging Analysts’ Ratings for ArQule Stock in July

By

Updated

Company overview

ArQule (ARQL) is a biopharmaceutical company with a focus on developing therapeutics for treating cancers and rare diseases. A leader in precision medical research, ArQule has five product candidates in its research pipeline. 

In the last five days, ArQule stock has risen from a low of $5.53 on July 5 to $6.86 on July 6. It closed 20.11% higher at $6.81 on July 6.

Article continues below advertisement

Analysts’ recommendations

Of the six analysts covering ArQule in July, two analysts gave the stock a “strong buy” rating. Four analysts gave it a “buy” rating. The mean rating for the stock is 1.67 with a target price of $6.96.

Peers’ ratings

Two of the eight analysts covering Exelixis (EXEL) in July gave the stock a “strong buy” rating, five analysts gave it a “buy” rating, and one analyst gave the stock a “hold” rating. The mean rating for Exelixis is 1.88 with a target price of $33.17.

In July, three of the seven analysts covering Array BioPharma (ARRY) gave the stock a “strong buy” rating, and four analysts gave it a “buy” rating. The mean rating for the stock is 1.57 with a target price of $23.29.

All three analysts covering Aveo Pharmaceuticals (AVEO) in July gave the stock a “buy” rating. The mean rating for the stock is 2.0 with a target price of $5.67.

In the next part of this series, we’ll take a look at ArQule’s financial performance.

Advertisement

More From Market Realist